Prognostic role and clinical significance of C-reactive protein-lymphocyte ratio in colorectal cancer

被引:20
作者
Meng, Yongsheng [1 ,2 ]
Long, Chenyan [3 ]
Huang, Xiaoliang [1 ,2 ]
Huang, Lihaoyun [1 ,2 ]
Liao, Lixian [1 ,2 ]
Tang, Weizhong [1 ,2 ]
Liu, Jungang [1 ,2 ]
机构
[1] Guangxi Med Univ Canc Hosp, Dept Gastrointestinal Surg, Div Colorectal & Anal Surg, Nanning, Guangxi Zhuang, Peoples R China
[2] Guangxi Clin Res Ctr Colorectal Canc, Nanning, Peoples R China
[3] Xiangya Sch Med, Dept Gen Surg 2, Zhuzhou Hosp, Changsha, Hunan, Peoples R China
关键词
Systemic inflammatory response; C-reactive protein; lymphocyte count; overall survival; colorectal cancer; SYSTEMIC INFLAMMATORY RESPONSE; COLON-CANCER; SURVIVAL;
D O I
10.1080/21655979.2021.1960768
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Systemic inflammatory response (SIRS) can be used as a potential prognostic marker in patients with colorectal cancer (CRC). The purpose of this study was to examine the predictive role of the C-reactive protein (CRP)-lymphocyte ratio (CLR) in the prognosis of CRC. We retrospectively analyzed the data of CRC patients who underwent surgery from 2004 to 2019. The clinicopathological characteristics and follow-up records were analyzed. According to a cutoff value of CLR, the patients were divided into the high and low groups. Kaplan-Meier curves and Cox proportional hazards regression model were applied to assess the overall survival (OS). Clinicopathological characteristics analysis showed that gender, age, BMI, lymphocyte count, tumor location, left- and right-sided CRC, differentiation, T stage, M stage, TNM stage, carcinoembryonic antigen (CEA), CLR, CRP, and microsatellite status were found to differ significantly between the high and low CLR groups. Kaplan-Meier curves revealed that the high CLR group had a shorter OS, and the elderly or right-sided CRC patients faced a worse prognosis. Multivariate analysis suggested that age (hazard ratio [HR]:1.011, P = 0.003), differentiation (HR:1.331, P = 0.000), TNM stage (HR:2.425, P = 0.000), CEA (HR:1.001, P = 0.025), CLR (HR:1.261, P = 0.014) were significant independent prognostic factors for OS. Subgroup analysis demonstrated that females or patients not receiving postoperative adjuvant chemotherapy with high CLR might suffer a worse prognosis. Overall, CLR can be applied as a promising prognostic marker in CRC patients and has great potential in guiding clinical work.
引用
收藏
页码:5138 / 5148
页数:11
相关论文
共 33 条
[1]   Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer [J].
Allin, Kristine H. ;
Nordestgaard, Borge G. .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (04) :155-170
[2]   Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel [J].
Araki, Kazuhiro ;
Ito, Yoshinori ;
Fukada, Ippei ;
Kobayashi, Kokoro ;
Miyagawa, Yoshimasa ;
Imamura, Michiko ;
Kira, Ayako ;
Takatsuka, Yuichi ;
Egawa, Chiyomi ;
Suwa, Hirofumi ;
Ohno, Shinji ;
Miyoshi, Yasuo .
BMC CANCER, 2018, 18
[3]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[4]   Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology [J].
Benson, Al B., III ;
Venook, Alan P. ;
Cederquist, Lynette ;
Chan, Emily ;
Chen, Yi-Jen ;
Cooper, Harry S. ;
Deming, Dustin ;
Engstrom, Paul F. ;
Enzinger, Peter C. ;
Fichera, Alessandro ;
Grem, Jean L. ;
Grothey, Axel ;
Hochster, Howard S. ;
Hoffe, Sarah ;
Hunt, Steven ;
Kamel, Ahmed ;
Kirilcuk, Natalie ;
Krishnamurthi, Smitha ;
Messersmith, Wells A. ;
Mulcahy, Mary F. ;
Murphy, James D. ;
Nurkin, Steven ;
Saltz, Leonard ;
Sharma, Sunil ;
Shibata, David ;
Skibber, John M. ;
Sofocleous, Constantinos T. ;
Stoffel, Elena M. ;
Stotsky-Himelfarb, Eden ;
Willett, Christopher G. ;
Wu, Christina S. ;
Gregory, Kristina M. ;
Freedman-Cass, Deborah .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (03) :370-398
[5]   C-reactive protein [J].
Black, S ;
Kushner, I ;
Samols, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48487-48490
[6]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[7]   Analysis of the intricate relationship between chronic inflammation and cancer [J].
Chai, Edna Zhi Pei ;
Siveen, Kodappully Sivaraman ;
Shanmugam, Muthu K. ;
Arfuso, Frank ;
Sethi, Gautam .
BIOCHEMICAL JOURNAL, 2015, 468 :1-15
[8]   The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review [J].
Dolan, Ross D. ;
Laird, Barry J. A. ;
Horgan, Paul G. ;
McMillan, Donald C. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 132 :130-137
[9]   The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[10]   Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival [J].
Frydenberg, H. ;
Thune, I. ;
Lofterod, T. ;
Mortensen, E. S. ;
Eggen, A. E. ;
Risberg, T. ;
Wist, E. A. ;
Flote, V. G. ;
Furberg, A-S ;
Wilsgaard, T. ;
Akslen, L. A. ;
McTiernan, A. .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) :345-354